Sevuparin sodium

STOCKHOLM, SWEDEN – March 31 2025: Modus Therapeutics Holding AB (“Modus”) today announces that the company has secured access to bridge financing of up to SEK 5.0 million from its largest shareholder, Karolinska Development AB. The financing enables Modus to maintain strong operational momentum in its ongoing Phase IIa study targeting anemia in chronic kidney disease (CKD). John Öhd, CEO of Modus Therapeutics, commented: “We are grateful for the continued support from our long-term investor Karolinska Development. This bridge financing is an important step in ensuring the progress of our clinical program, with current focus on completing Part 1 of our Phase IIa CKD study and preparing for Part 2. In parallel, we continue to actively evaluate options for long-term financing.” For more information on Modus Therapeutics, please contact: John Öhd, CEO, Modus Therapeutics Phone: +46 (0) 70 766 80 97 Email: john.ohd@modustx.com This information is information that Modus Therapeutics Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-31 14:00 CEST. Certified Adviser Svensk Kapitalmarknadsgranskning AB Website: www.skmg.se About Modus Therapeutics and sevuparin Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com. Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration. Attachments Modus Therapeutics Secures Bridge Financing from Karolinska Development

STOCKHOLM, SWEDEN - 20 February 2025: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes the year-end report for 2024. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report. John Öhd, Modus Therapeutics' CEO, commented:”2024 has been a transformational year for Modus Therapeutics, marked by groundbreaking clinical progress and a reinforced pipeline. With a clear vision and strong scientific foundations, we are poised to drive innovation in delivering innovative treatments for disorders of high need.” The fourth quarter in figures The loss after tax amounted to TSEK 4 713 (4 069). The loss per share amounted to SEK 0,13 (0,18). The cash flow from current operations was negative in the amount of TSEK 3 619 (3 126). The full year in figures The loss after tax amounted to TSEK 15 545 (17 897). The loss per share amounted to SEK 0,43 (1,01). The cash flow from current operations was negative in the amount of TSEK 14 681 (16 684). Important events during the fourth quarter Modus Therapeutics receives a recruitment update from the collaborative Phase Ib study in severe malaria. Modus Therapeutics Receives Approval to Initiate a Phase IIa Clinical Trial for Chronic Kidney Disease (CKD). Modus Therapeutics secures access to bridge financing of 5 MSEK from Karolinska Development. New Article on Sevuparin Published in HemaSphere. Modus Therapeutics Initiates Phase II Study with Sevuparin for the Treatment of Chronic Kidney Disease with Anemia. Modus Therapeutics presents LPS Study Data at Pharmacology 2024. Important events after the end of the period Modus Therapeutics receives a recruitment update from the collaborative Phase Ib study in severe malaria. CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on February 20 at 11:00. Link to Interview: https://www.youtube.com/watch?v=mZnLJkp0phc For more information on Modus Therapeutics, please contact: John Öhd, CEO, Modus Therapeutics Phone: +46 (0) 70 766 80 97 Email: john.ohd@modustx.com This information is information that Modus Therapeutics Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-20 08:00 CET. Certified Adviser Svensk Kapitalmarknadsgranskning AB Website: www.skmg.se About Modus Therapeutics and sevuparin Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com. Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration. Attachments Modus Year End Report 2024